Literature DB >> 28676708

IBD: To switch or not to switch: that is the biosimilar question.

Silvio Danese1, Laurent Peyrin-Biroulet2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28676708     DOI： 10.1038/nrgastro.2017.86

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  8 in total

1.  ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.

Authors:  Silvio Danese; Gionata Fiorino; Tim Raine; Marc Ferrante; Karen Kemp; Jaroslaw Kierkus; Peter L Lakatos; Gerassimos Mantzaris; Janneke van der Woude; Julian Panes; Laurent Peyrin-Biroulet
Journal:  J Crohns Colitis       Date:  2016-12-07       Impact factor: 9.071

Review 2.  Biosimilars in IBD: from theory to practice.

Authors:  Silvio Danese; Stefanos Bonovas; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

3.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Authors:  Kristin K Jørgensen; Inge C Olsen; Guro L Goll; Merete Lorentzen; Nils Bolstad; Espen A Haavardsholm; Knut E A Lundin; Cato Mørk; Jørgen Jahnsen; Tore K Kvien
Journal:  Lancet       Date:  2017-05-11       Impact factor: 79.321

4.  Biosimilars: the science of extrapolation.

Authors:  Martina Weise; Pekka Kurki; Elena Wolff-Holz; Marie-Christine Bielsky; Christian K Schneider
Journal:  Blood       Date:  2014-10-08       Impact factor: 22.113

5.  Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.

Authors:  Silvio Danese; Gionata Fiorino; Pierre Michetti
Journal:  J Crohns Colitis       Date:  2016-04-25       Impact factor: 9.071

6.  Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.

Authors:  Laurent Peyrin-Biroulet; Sanna Lönnfors; Xavier Roblin; Silvio Danese; Luisa Avedano
Journal:  J Crohns Colitis       Date:  2016-07-31       Impact factor: 9.071

7.  Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.

Authors:  Violeta Razanskaite; Marion Bettey; Louise Downey; Julia Wright; James Callaghan; Miles Rush; Simon Whiteoak; Sarah Ker; Kim Perry; Caron Underhill; Eren Efrem; Iftikar Ahmed; Fraser Cummings
Journal:  J Crohns Colitis       Date:  2017-06-01       Impact factor: 9.071

8.  Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany.

Authors:  John Waller; Emma Sullivan; James Piercy; Christopher M Black; Sumesh Kachroo
Journal:  Patient Prefer Adherence       Date:  2017-03-13       Impact factor: 2.711
  8 in total
  4 in total

Review 1.  The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.

Authors:  HoUng Kim; Rieke Alten; Luisa Avedano; Axel Dignass; Fernando Gomollón; Kay Greveson; Jonas Halfvarson; Peter M Irving; Jørgen Jahnsen; Péter L Lakatos; JongHyuk Lee; Souzi Makri; Ben Parker; Laurent Peyrin-Biroulet; Stefan Schreiber; Steven Simoens; Rene Westhovens; Silvio Danese; Ji Hoon Jeong
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

2.  Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease.

Authors:  Kevin J Roberts; Marion F Cubitt; Timothy M Carlton; Lurdes Rodrigues-Duarte; Luana Maggiore; Ray Chai; Simon Clare; Katherine Harcourt; Thomas T MacDonald; Keith P Ray; Anna Vossenkämper; Michael R West; J Scott Crowe
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

Review 3.  Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

Authors:  Eduardo Mysler; Valderilio Feijó Azevedo; Silvio Danese; Daniel Alvarez; Noriko Iikuni; Beverly Ingram; Markus Mueller; Laurent Peyrin-Biroulet
Journal:  Drugs       Date:  2021-10-27       Impact factor: 9.546

4.  The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review.

Authors:  Liese Barbier; Hans C Ebbers; Paul Declerck; Steven Simoens; Arnold G Vulto; Isabelle Huys
Journal:  Clin Pharmacol Ther       Date:  2020-04-30       Impact factor: 6.875
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.